CV Risk Management in T2DM: What Did We Learn from ADA 2016?

Program Overview

ADA Scientific Sessions

T2DM and CVD

Progression to Diabetes Is Associated With an Increased Incidence of CVD Among Persons With IGT

Impact of Progression to Diabetes on CVD Events

Glucose-Lowering and Vascular Benefits

Safety of Glucose-Lowering Drugs

Ongoing CVOTs in Patients With T2DM

Mortality Findings From the EXAMINE Trial[a]

EXAMINE: CV Mortality Findings

EMPA-REG OUTCOME: Primary Endpoint -- 3-Point MACE*

Effect of Empagliflozin on CV Death in Subgroups by Age: Results From EMPA-REG OUTCOME

Effect of Empagliflozin on HF Outcomes in Subgroups by Age: Results From EMPA-REG OUTCOME

Incidence Rates of CV Death by LDL-C at Baseline

LEADER: Study Design

LEADER: Primary and Key Secondary Outcomes

LEADER: Study Population Baseline Characteristics

LEADER: Primary Outcome*

LEADER: Primary Outcome Subgroup Analyses

LEADER: Primary Outcome Subgroup Analyses (cont)

LEADER: CV Death

LEADER: All-Cause Death

LEADER: Time to Nonfatal MI

LEADER: Time to Nonfatal Stroke

LEADER: Hospitalization for HF

LEADER: AEs Leading to Permanent Treatment Discontinuation

LEADER: Selected AEs of Special Interest

LEADER: Risk for Hypoglycemia

SUSTAIN 6

Conclusions

Conclusions (cont)

Abbreviations

Abbreviations (cont)